Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325978 | 0.91 | CTSK (0.39) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL27343844 | 0.88 | CA2 (0.48) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL7804092 | 0.88 | CA2 (0.48) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1618549 | 0.86 | GPR84 (0.46) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL3326024 | 0.86 | ALDH1A1 (0.41) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL28657458 | 0.85 | GPR84 (0.48) | CA2MAPK1SLC1A2SLC1A1GRIK1 | |
| SCHEMBL7100720 | 0.85 | GPR84 (0.48) | CA2MAPK1SLC1A2SLC1A1GRIK1 | |
| SCHEMBL28766383 | 0.85 | GPR84 (0.48) | CA2MAPK1SLC1A2SLC1A1GRIK1 | |
| SCHEMBL9659765 | 0.85 | GPR84 (0.48) | CA2MAPK1SLC1A2SLC1A1GRIK1 | |
| SCHEMBL28994389 | 0.85 | GPR84 (0.48) | CA2MAPK1SLC1A2SLC1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025098432-A1 | mIDH1/NAMPT DUAL-TARGET INHIBITOR AND USE THEREOF | 中国药科大学 | 2025-05-15 | — | — | WO | disclosed |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2024-12-12 | — | — | US | disclosed |
| CN-117510484-B | MIDH1/NAMPT double-target inhibitor and application thereof | 中国药科大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-117510484-A | mIDH1/NAMPT double-target inhibitor and application thereof | 中国药科大学 | 2024-02-06 | — | — | CN | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-9505779-B2 | Tacrolimus analogues, a neuroprotective composition comprising the same, an immunosuppressive composition comprising the same, a method for preparing the same, and a mutant for producing the same | INTRON BIOTECHNOLOGY, INC. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-9505779-B2 | Tacrolimus analogues, a neuroprotective composition comprising the same, an immunosuppressive composition comprising the same, a method for preparing the same, and a mutant for producing the same | INTRON BIOTECHNOLOGY, INC. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-20130230559-A1 | NOVEL TACROLIMUS ANALOGUES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME | Ewha University - Industry Collaboration Foundatio (KR) | 2013-09-05 | — | — | US | disclosed |
| US-20130230559-A1 | NOVEL TACROLIMUS ANALOGUES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME | Ewha University - Industry Collaboration Foundatio (KR) | 2013-09-05 | — | — | US | disclosed |
| WO-2012026665-A1 | NOVEL TACROLIMUS DERIVATIVES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MCL1, CD44, CRABP2 | CHRM1 2541/4885AKR1A1 3336/4885CHRM3 1087/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | CHRM1 192/4885AKR1A1 1818/4885CHRM3 413/4885 |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | CHRM1 2541/4885AKR1A1 3336/4885CHRM3 1087/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | CHRM1 2541/4885AKR1A1 3336/4885CHRM3 1087/4885 |
| US-20130230559-A1 | NOVEL TACROLIMUS ANALOGUES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME | CTSA, TPSAB1, ARSA | CHRM1 1826/4885AKR1A1 999/4885CHRM3 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.